WO2010034006A3 - Micro-arn-101 suppresseur de tumeur putatif modulant l'epigenome cancereux par repression de la proteine ezh2 du groupe polycomb - Google Patents

Micro-arn-101 suppresseur de tumeur putatif modulant l'epigenome cancereux par repression de la proteine ezh2 du groupe polycomb Download PDF

Info

Publication number
WO2010034006A3
WO2010034006A3 PCT/US2009/057890 US2009057890W WO2010034006A3 WO 2010034006 A3 WO2010034006 A3 WO 2010034006A3 US 2009057890 W US2009057890 W US 2009057890W WO 2010034006 A3 WO2010034006 A3 WO 2010034006A3
Authority
WO
WIPO (PCT)
Prior art keywords
repressing
modulates
tumor suppressor
group protein
polycomb group
Prior art date
Application number
PCT/US2009/057890
Other languages
English (en)
Other versions
WO2010034006A2 (fr
Inventor
Jeffrey J. Friedman
Gangning Liang
Peter A. Jones
Original Assignee
University Of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Southern California filed Critical University Of Southern California
Priority to US13/119,699 priority Critical patent/US20110224284A1/en
Publication of WO2010034006A2 publication Critical patent/WO2010034006A2/fr
Publication of WO2010034006A3 publication Critical patent/WO2010034006A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Abstract

L'invention concerne en général le profilage de micro-ARN pour certaines maladies. L'invention concerne plus particulièrement des méthodes et des compostions de micro-ARN destinées à inhiber la croissance et la formation de tumeurs.
PCT/US2009/057890 2008-09-22 2009-09-22 Micro-arn-101 suppresseur de tumeur putatif modulant l'epigenome cancereux par repression de la proteine ezh2 du groupe polycomb WO2010034006A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/119,699 US20110224284A1 (en) 2008-09-22 2009-09-22 Putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9911408P 2008-09-22 2008-09-22
US61/099,114 2008-09-22

Publications (2)

Publication Number Publication Date
WO2010034006A2 WO2010034006A2 (fr) 2010-03-25
WO2010034006A3 true WO2010034006A3 (fr) 2010-05-27

Family

ID=42040204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/057890 WO2010034006A2 (fr) 2008-09-22 2009-09-22 Micro-arn-101 suppresseur de tumeur putatif modulant l'epigenome cancereux par repression de la proteine ezh2 du groupe polycomb

Country Status (2)

Country Link
US (1) US20110224284A1 (fr)
WO (1) WO2010034006A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109745316B (zh) * 2012-04-13 2023-01-24 Epizyme股份有限公司 用于治疗癌症的联合治疗

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006577A2 (fr) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions et méthodes pour inhiber la protéine ezh2
US20120059159A1 (en) * 2009-05-25 2012-03-08 Carola Ponzetto Differentiation therapy for sarcomas
SG180031A1 (en) * 2010-10-15 2012-05-30 Agency Science Tech & Res Combination treatment of cancer
US20140107176A1 (en) * 2012-10-12 2014-04-17 Agency For Science, Technology And Research Method of modulating a prostate cancer cell
WO2020227604A1 (fr) * 2019-05-08 2020-11-12 Nova Southeastern University Régulation de la réparation d'excision de nucléotides (ner) par microarn pour le traitement du cancer du sein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713938A2 (fr) * 2004-02-09 2006-10-25 Thomas Jefferson University Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers
EP2471924A1 (fr) * 2004-05-28 2012-07-04 Asuragen, INC. Procédés et compositions impliquant du microARN
WO2009006577A2 (fr) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions et méthodes pour inhiber la protéine ezh2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAUNDERS ET AL.: "Human polymorphism at microRNAs and microRNA target sites.", PNAS, vol. 104, no. 9, 2007, pages 3301 - 3305 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109745316B (zh) * 2012-04-13 2023-01-24 Epizyme股份有限公司 用于治疗癌症的联合治疗

Also Published As

Publication number Publication date
WO2010034006A2 (fr) 2010-03-25
US20110224284A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
WO2010037041A3 (fr) Agents se liant aux récepteurs frizzled et leurs utilisations
WO2010141738A3 (fr) Compositions et procédé pour inhiber la croissance d'une tumeur
WO2008154249A3 (fr) Marqueurs d'expression de gène de résistance tumorale à un traitement par inhibiteur her2
WO2018091740A3 (fr) Nouveaux anticorps et utilisations associées
WO2012016133A3 (fr) Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
WO2011103016A3 (fr) Compositions et méthodes d'inhibition d'ezh2
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
WO2012058588A3 (fr) Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci
EA201001639A1 (ru) Композиции и способы их получения и применения
WO2012058592A3 (fr) Molécules non antagonistes se liant au récepteur egf et immunoconjugués de celles-ci
AU2016219704A1 (en) Anti-Notch1 antibodies
WO2009039337A3 (fr) Inhibition de l'angiogenèse
EP3722810A3 (fr) Profilage moléculaire de tumeurs
WO2012019024A3 (fr) Molécules se liant à her3 et leurs immunoconjugués
WO2009126310A3 (fr) Procédés d’identification et utilisation d’agents ciblant les cellules souches cancéreuses
WO2012088290A3 (fr) Protéines de liaison à trois domaines variables et leurs utilisations
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
WO2009002947A3 (fr) Composés et peptides de liaison au récepteur de trail
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
WO2008089397A3 (fr) Marqueurs du cancer adrb2
MX370721B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09815396

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13119699

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09815396

Country of ref document: EP

Kind code of ref document: A2